Collectively, these studies reveal that Y33 IC potently stimulates CD8+ T cell expansion, activation, and effector functions without eliciting toxicities typically associated with IL-2 treatment, rendering this molecule a promising candidate for cancer immunotherapy. Here, CD8A is linked to cancer.